BRAF and melanoma: Highly recurrent mutations in the BRAF V600 codon, which accounts for 35-50% of melanoma, and the Q61 codon, which accounts for 10-25% of melanoma, contribute to the evolution of highly selective kinase inhibitors for the MAPK pathway (9).